PAVM (PAVmed Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PAVM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-13 | Victoria Tou-ho Lee | Chief Medical Officer | A | — | — |
| 2026-04-03 | Timothy E Baxter | Director | A | — | — |
| 2026-04-03 | Sundeep Agrawal | Director | A | — | — |
| 2026-04-03 | DENNIS M MCGRATH | President and CFO | A | — | — |
| 2026-04-03 | Michael Adam Gordon | General Counsel | A | — | — |
| 2026-04-03 | Michael J Glennon | Director | A | — | — |
| 2026-04-03 | Ronald M Sparks | Director | A | — | — |
| 2026-04-03 | Shaun O'Neil | Chief Operating Officer | A | — | — |
| 2026-04-03 | Debra White | Director | A | — | — |
| 2026-04-03 | Lishan Aklog | Chairman and CEO | A | — | — |
| 2025-10-02 | Debra White | Director | A | — | — |
| 2025-10-02 | Ronald M Sparks | Director | A | — | — |
| 2025-10-02 | Sundeep Agrawal | Director | A | — | — |
| 2025-10-02 | Michael J Glennon | Director | A | — | — |
| 2025-10-02 | Shaun O'Neil | Chief Operating Officer | A | — | — |
| 2025-10-02 | DENNIS M MCGRATH | President and CFO | A | — | — |
| 2025-10-02 | Timothy E Baxter | Director | A | — | — |
| 2025-10-02 | Lishan Aklog | Chairman and CEO | A | — | — |
| 2025-10-02 | Michael Adam Gordon | General Counsel | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chairman and CEO | 367,518 | — |
| — | President and CFO | 186,695 | — |
| — | Chief Operating Officer | 115,598 | — |
| — | General Counsel | 115,000 | — |
| — | Chief Medical Officer | 71,666 | — |
| — | Director | 21,653 | — |
| — | Director | 21,097 | — |
| — | Director | 21,097 | — |
| — | Director | 21,097 | — |
| — | Director | 19,337 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PAVM quote page; the site-wide leaderboard is on the insider transactions hub.